Literature DB >> 3582475

Effect of aluminum phosphate on the bioavailability of ranitidine.

H Albin, G Vinçon, B Begaud, C Bistue, P Perez.   

Abstract

The effect of aluminum phosphate on the bioavailability of ranitidine has been investigated in 10 young, healthy volunteers. Following a random cross over design, each subject took at a 1 week interval 150 mg ranitidine alone or with 11 g aluminum phosphate. Plasma and urine ranitidine levels were measured by HPLC. The antacid reduced both the maximum plasma ranitidine concentration by 40% and the area under the curve by 30%. Elimination of ranitidine was not changed. The results indicate that aluminum phosphate significantly diminished the bioavailability of ranitidine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582475     DOI: 10.1007/bf00609966

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

Review 1.  Antacid therapy and drug kinetics.

Authors:  A Hurwitz
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 2.  Interactions affecting drug absorption.

Authors:  P G Welling
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

3.  High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.

Authors:  G W Mihaly; A T Marino; L K Webster; D B Jones; W J Louis; R A Smallwood
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

4.  High dose of antacid reduces bioavailability of ranitidine.

Authors:  K Frislid; A Berstad
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-23

5.  [Bioavailability of procainamide and disopyramide with and without concomitant administration of an antacid: aluminium phosphate (author's transl)].

Authors:  H Albin; G Vinçon; D Bertolaso; J Dangoumau
Journal:  Therapie       Date:  1981 Sep-Oct       Impact factor: 2.070

6.  Analysis of ranitidine in serum by high performance liquid chromatography.

Authors:  H M Vandenberghe; S M MacLeod; W A Mahon; P A Lebert; S J Soldin
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

Review 7.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

8.  Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone.

Authors:  H Albin; G Vincon; F Demotes-Mainard; B Begaud; A Bedjaoui
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Bioavailability of ketoprofen in man with and without concomitant administration of aluminium phosphate.

Authors:  J L Brazier; J N Tamisier; D Ambert; A Bannier
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

  9 in total
  3 in total

1.  Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.

Authors:  C A Knupp; F M Graziano; R M Dixon; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.